Market Overview:
The global non-invasive cancer diagnostics market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, technological advancements in non-invasive cancer diagnostics, and rising demand for early diagnosis and treatment of cancer. The global non-invasive cancer diagnostics market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into circulating tumor cells (CTCs), circulating tumor nucleic acids (CTNAs), and exosomes. The CTCs segment is expected to account for the largest share of the global non-invasive cancer diagnostics market in 2018 owing to their ability to detect tumors at an early stage. On the basis of application, the market is divided into blood tests, urine tests, and saliva tests. The blood test segment accounted for majority share of this market in 2017 due to its high usage rate across various applications such as oncology clinics & hospitals laboratories; research institutes; pathology labs; drug discovery centers; biotechnology companies etc.
Product Definition:
Non-invasive cancer diagnostics are tests that can be used to detect cancer without having to perform surgery. This type of diagnosis is important because it can help doctors determine if a person has cancer and whether or not the cancer is treatable without having to perform surgery.
CTCs:
CTCs are also known as clonal expansions. It is a group of cells that grow in an abnormal way and has the ability to subdivide into other similar looking cells. These formations have a special property, they can grow faster than the regular cell growth and have more genetic material (DNA & RNA). CTCs are identified by their large size, shape and appearance which makes them stand out from the other normal body cells.
CTNAS:
CTNAs ( Compact Targeted Nucleic Acid Amplification) are a class of noninvasive genetic tests that involve the use of DNA amplification to detect cancer. The test works by detecting an abnormal gene which is responsible for causing cancer. This abnormality is known as a tumor gene and can be either inherited from the person's parents or acquired during their lifetime.
Application Insights:
The blood cancer segment dominated the global market in 2017. The increasing prevalence of blood disorders, such as myelodysplastic syndrome and acute lymphoblastic leukemia, is anticipated to drive the growth of this segment during the forecast period. In addition, an increase in research initiatives for early diagnosis of these diseases is expected to further boost growth over the coming years.
Urine and saliva tests are also anticipated to witness significant growth during the forecast period owing to their ability to detect genetic abnormalities that may not show up in other testing methods. For instance, a recent study found that urine test can be used along with other diagnostic methods for early detection of chromosomal aberrations associated with high-risk prostate cancer patients. This finding is expected to trigger new research on application-based non-invasive cancer diagnostics techniques over next few years.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high adoption rate of advanced technologies, and availability of well-developed healthcare infrastructure. In addition, rising prevalence of cancer is expected to further boost regional growth during the forecast period. Asia Pacific is anticipated to witness lucrative CAGR over the forecast period owing to increasing government initiatives for early diagnosis coupled with improving healthcare facilities in emerging countries such as China and India. Moreover, rising awareness about various non-invasive methods used for cancer detection will drive regional demand during the forecast period. Furthermore, an increase in number of research studies on humanized mice models will positively impact industry growth over this timeframe (Kumar et al., 2016).
Moreover, growing R&D activities by major companies pertaining towards development & launch new products are also contributing towards overall revenue generation within region (Gates et al., 2015).
Growth Factors:
- Increasing incidence of cancer: The global incidence of cancer is increasing at an alarming rate. This is primarily due to the aging population and the rising prevalence of lifestyle-related cancers. According to the World Health Organization, there were 14 million new cases of cancer in 2012, and this number is expected to rise to 21 million by 2030. This presents a huge opportunity for non-invasive cancer diagnostics market players.
- Advances in technology: Technological advances are paving the way for novel non-invasive diagnostic techniques that are more accurate and sensitive than traditional methods. For instance, next-generation sequencing (NGS) technology can be used to detect genetic mutations associated with various types of cancers. This is helping to improve diagnosis accuracy and enable earlier treatment intervention.
- Growing demand for personalized medicine: There is growing demand for personalized medicine, especially among patients with advanced or metastatic cancers who do not respond well to traditional therapies such as chemotherapy or radiation therapy . Non-invasive diagnostic tests that can identify specific genetic mutations associated with a patient’s tumor can help guide treatment decisions and improve outcomes .
Scope Of The Report
Report Attributes
Report Details
Report Title
Non-Invasive Cancer Diagnostics Market Research Report
By Type
CTCs, CTNAS, Exosomes
By Application
Blood, Urine, Saliva
By Companies
Gen-Probe Inc, Digene Corporation, Quest Diagnostics Inc, Cancer, Genetics Inc, BIOVIEW Inc, AVIVA Biosciences Corporation, Laboratory Corporation of America Holdings (LabCorp), A&G Pharmaceutical, Affymetrix Inc, Precision Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
131
Number of Tables & Figures
92
Customization Available
Yes, the report can be customized as per your need.
Global Non-Invasive Cancer Diagnostics Market Report Segments:
The global Non-Invasive Cancer Diagnostics market is segmented on the basis of:
Types
CTCs, CTNAS, Exosomes
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Blood, Urine, Saliva
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Gen-Probe Inc
- Digene Corporation
- Quest Diagnostics Inc
- Cancer, Genetics Inc
- BIOVIEW Inc
- AVIVA Biosciences Corporation
- Laboratory Corporation of America Holdings (LabCorp)
- A&G Pharmaceutical
- Affymetrix Inc
- Precision Therapeutics
Highlights of The Non-Invasive Cancer Diagnostics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CTCs
- CTNAS
- Exosomes
- By Application:
- Blood
- Urine
- Saliva
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Non-Invasive Cancer Diagnostics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Non-invasive cancer diagnostics is a term used to describe diagnostic methods that do not require surgery or other invasive procedures. These methods can include blood tests, scans, and even genetic testing.
Some of the major players in the non-invasive cancer diagnostics market are Gen-Probe Inc, Digene Corporation, Quest Diagnostics Inc, Cancer, Genetics Inc, BIOVIEW Inc, AVIVA Biosciences Corporation, Laboratory Corporation of America Holdings (LabCorp), A&G Pharmaceutical, Affymetrix Inc, Precision Therapeutics.
The non-invasive cancer diagnostics market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Non-Invasive Cancer Diagnostics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Non-Invasive Cancer Diagnostics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Non-Invasive Cancer Diagnostics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Non-Invasive Cancer Diagnostics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Non-Invasive Cancer Diagnostics Market Size & Forecast, 2020-2028
4.5.1 Non-Invasive Cancer Diagnostics Market Size and Y-o-Y Growth
4.5.2 Non-Invasive Cancer Diagnostics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 CTCs
5.2.2 CTNAS
5.2.3 Exosomes
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Blood
6.2.2 Urine
6.2.3 Saliva
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Non-Invasive Cancer Diagnostics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Non-Invasive Cancer Diagnostics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 CTCs
9.6.2 CTNAS
9.6.3 Exosomes
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Blood
9.10.2 Urine
9.10.3 Saliva
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 CTCs
10.6.2 CTNAS
10.6.3 Exosomes
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Blood
10.10.2 Urine
10.10.3 Saliva
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 CTCs
11.6.2 CTNAS
11.6.3 Exosomes
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Blood
11.10.2 Urine
11.10.3 Saliva
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 CTCs
12.6.2 CTNAS
12.6.3 Exosomes
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Blood
12.10.2 Urine
12.10.3 Saliva
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 CTCs
13.6.2 CTNAS
13.6.3 Exosomes
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Blood
13.10.2 Urine
13.10.3 Saliva
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Non-Invasive Cancer Diagnostics Market: Competitive Dashboard
14.2 Global Non-Invasive Cancer Diagnostics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Gen-Probe Inc
14.3.2 Digene Corporation
14.3.3 Quest Diagnostics Inc
14.3.4 Cancer, Genetics Inc
14.3.5 BIOVIEW Inc
14.3.6 AVIVA Biosciences Corporation
14.3.7 Laboratory Corporation of America Holdings (LabCorp)
14.3.8 A&G Pharmaceutical
14.3.9 Affymetrix Inc
14.3.10 Precision Therapeutics
